Pluristem Therapeutics, Compugen: Early Volume Plays

NEW YORK (TheStreet) -- Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.

Pluristem Therapeutics (PSTI) jumped by 9 cents, or 8%, to $1.22 in the premarket session after the company said it has received approval from an independent Data Safety Monitoring Board (DSMB) to advance to the final dose level with its placenta-derived cell therapy product, PLX-PAD, in a Phase I dose-escalating clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). The 50-day average daily volume for Pluristem is 137,000, according to the Nasdaq.

Compugen (CGEN) gained 20 cents, or 4.4%, to $4.76 in the premarket session after the company appointed Anat Cohen-Dayag, Ph.D. as president and CEO, and Martin Gerstel as chairman. Previously, Cohen-Dayag and Gerstel served as co-CEOs of the company. The 50-day average daily volume for Compugen is 1.78 million.

Antares Pharma (AIS) was poised to trade higher after the company announced the completion of patient enrollment in Phase 3 Pivotal Trial of Anturol for the treatment of overactive bladder. The three-month average daily volume for Antares is 356,000, according to Yahoo! Finance.

China Security & Surveillance Technology (CSR) rallied by 70 cents, or 9.7%, to $7.95 in the premarket session even after the company missed the Thomson Reuters average earnings and revenue estimates with its fourth-quarter results. However, the company reaffirmed its earnings and revenue guidance for 2010. The three-month average daily volume for China Security & Surveillance is 1.12 million.

-- Written by Robert Holmes in Boston.

Check out all of Tuesday's high-volume, under-$5 stocks at the Dollar Store

Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.

>To order reprints of this article, click here: Reprints